Literature DB >> 24670052

Importance of ABCC1 for cancer therapy and prognosis.

Tereza Kunická1, Pavel Souček.   

Abstract

Multidrug resistance presents one of the most important causes of cancer treatment failure. Numerous in vitro and in vivo data have made it clear that multidrug resistance is frequently caused by enhanced expression of ATP-binding cassette (ABC) transporters. ABC transporters are membrane-bound proteins involved in cellular defense mechanisms, namely, in outward transport of xenobiotics and physiological substrates. Their function thus prevents toxicity as carcinogenesis on one hand but may contribute to the resistance of tumor cells to a number of drugs including chemotherapeutics on the other. Within 48 members of the human ABC superfamily there are several multidrug resistance-associated transporters. Due to the well documented susceptibility of numerous drugs to efflux via ABC transporters it is highly desirable to assess the status of ABC transporters for individualization of treatment by their substrates. The multidrug resistance associated protein 1 (MRP1) encoded by ABCC1 gene is one of the most studied ABC transporters. Despite the fact that its structure and functions have already been explored in detail, there are significant gaps in knowledge which preclude clinical applications. Tissue-specific patterns of expression and broad genetic variability make ABCC1/MRP1 an optimal candidate for use as a marker or member of multi-marker panel for prediction of chemotherapy resistance. The purpose of this review was to summarize investigations about associations of gene and protein expression and genetic variability with prognosis and therapy outcome of major cancers. Major advances in the knowledge have been identified and future research directions are highlighted.

Entities:  

Keywords:  Drug; expression; polymorphism; prediction; resistance

Mesh:

Substances:

Year:  2014        PMID: 24670052     DOI: 10.3109/03602532.2014.901348

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  18 in total

1.  3D-QSAR AND CONTOUR MAP ANALYSIS OF TARIQUIDAR ANALOGUES AS MULTIDRUG RESISTANCE PROTEIN-1 (MRP1) INHIBITORS.

Authors:  Prathusha Kakarla; Madhuri Inupakutika; Amith R Devireddy; Shravan Kumar Gunda; Thomas Mark Willmon; K C Ranjana; Ugina Shrestha; Indrika Ranaweera; Alberto J Hernandez; Sharla Barr; Manuel F Varela
Journal:  Int J Pharm Sci Res       Date:  2016-02-01

Review 2.  Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins.

Authors:  Dustin R Walsh; Thomas D Nolin; Peter A Friedman
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 3.  Cancer stem cells and chemoresistance: The smartest survives the raid.

Authors:  Jihe Zhao
Journal:  Pharmacol Ther       Date:  2016-02-17       Impact factor: 12.310

4.  Abcc1 and Ggt5 support lymphocyte guidance through export and catabolism of S-geranylgeranyl-l-glutathione.

Authors:  Antonia E Gallman; Finn D Wolfreys; David N Nguyen; Moriah Sandy; Ying Xu; Jinping An; Zhongmei Li; Alexander Marson; Erick Lu; Jason G Cyster
Journal:  Sci Immunol       Date:  2021-06-04

5.  High ABCG4 Expression Is Associated with Poor Prognosis in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin-Based Chemotherapy.

Authors:  Guang Yang; Xue-Jiao Wang; Li-Jun Huang; Yong-An Zhou; Feng Tian; Jin-Bo Zhao; Peng Chen; Bo-Ya Liu; Miao-Miao Wen; Xiao-Fei Li; Zhi-Pei Zhang
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

Review 6.  Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance.

Authors:  Yi-Jun Wang; Yun-Kai Zhang; Rishil J Kathawala; Zhe-Sheng Chen
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

7.  Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes.

Authors:  Veronika Vymetalkova; Pavel Soucek; Tereza Kunicka; Katerina Jiraskova; Veronika Brynychova; Barbara Pardini; Vendula Novosadova; Zdena Polivkova; Katerina Kubackova; Renata Kozevnikovova; Miloslav Ambrus; Ludmila Vodickova; Alessio Naccarati; Pavel Vodicka
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

8.  Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy.

Authors:  Elisa Donnard; Paula F Asprino; Bruna R Correa; Fabiana Bettoni; Fernanda C Koyama; Fabio C P Navarro; Rodrigo O Perez; John Mariadason; Oliver M Sieber; Robert L Strausberg; Andrew J G Simpson; Denis L F Jardim; Luiz Fernando L Reis; Raphael B Parmigiani; Pedro A F Galante; Anamaria A Camargo
Journal:  Oncotarget       Date:  2014-10-15

9.  Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance.

Authors:  Xiwei Yu; Guang Yang; Yijie Shi; Chang Su; Ming Liu; Bo Feng; Liang Zhao
Journal:  Int J Nanomedicine       Date:  2015-11-12

10.  Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.

Authors:  David W Greening; Hong Ji; Maoshan Chen; Bruce W S Robinson; Ian M Dick; Jenette Creaney; Richard J Simpson
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.